This Plain Language Summary of Publication article (PLSP) from Future Neurology examined major depressive disorder, which causes low mood and reduced life engagement, making patient engagement an important treatment goal. This summary covers three studies on brexpiprazole (an atypical antipsychotic for depression): one developed a life engagement questionnaire, while two others used it to assess whether brexpiprazole improved life engagement and depression symptoms.

Visit the site using this link to read the article.

This PLSP is based on 3 articles called ‘Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR)’ and was published in the Journal of Psychiatric Research. 

‘Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data’ and was published in the Journal of Psychiatric Research.

‘Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d’appoint pour l’engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4’ and was published in the Canadian Journal of Psychiatriy.

Visit Elsevier using the link to read the original article.

Visit Elsevier using the link to read the original article.

Visit Sage Journals using the link to read the original article.